Budget impact of methylphenidate modified release tablet choice

The latest in the RDTC’s prescribing bulletin series covers methylphenidate, and highlights the difference in cost between bioequivalent methylphenidate modified release (MR) tablets. It considers the budget impact of MR tablet choice and shows the yearly primary care spend on all methylphenidate XL tablets, and the proportion of this spend on each of the available brands.

This bulletin, and our others, are available from the Prescribing Bulletins page.

Monthly formulary amendments – March 2023

A Monthly Formulary Amendments document covering guidance and alerts published in March 2023 is now available.

The purpose of the document is to support consistent decision making by APCs. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

This document is available alongside previous editions on the formulary amendments page.